2022, Number 3
The Mid-ventricular hypertrophic obstructive cardiomyopathy associated to coronary ectasia and artery intramyocardial bridging.
Full text
Language: Spanish
References: 6
Page: 1-3
PDF size: 639.23 Kb.
ABSTRACT
The hypertrophic cardiomyopathy (HCM) is a hereditary disease defined as an increase in the wall thickness in one or more myocardial segments in the absent of any other cardiac, systemic or metabolic condition that may justify this disease. It is of autosomal dominant transmission due to mutations in various cardiac sarcomere protein genes. HCM is divided into obstructive and non-obstructive. The former includes the mid-ventricular variant, a rare form of presentation that could be accompanied or not by apical aneurysm, ventricular arrhythmia, and sudden death. It is described the case of a 54-year-old male patient, with an evident obstructive HCM, mid-ventricular variant, associated to Markis type I coronary ectasia, myocardial bridging in the middle distal segment of the anterior descending artery, in which the physical exam and the imaging studies played an important role for the diagnosis.REFERENCES
Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P, et al. 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2020 [acceso 20/11/2020];142(25):e558-e631. Disponible en: https://www.acc.org/latest-in-cardiology/ten-points-to-remember/2020/11/18/18/47/2020-aha-acc-guideline-for-hcm-gl-hcm
Penas M, Mosquera I, Bouzas B, Vázquez J, Castro A. El electrocardiograma en la miocardiopatía hipertrófica apical. Presentación de un caso con manifestaciones únicas. Rev Esp Cardiol. 1999 [acceso 13/11/2021];52:1148-50. Disponible en: https://www.revespcardiol.org/en-el-electrocardiogramamiocardiopatia-hipertrofica-apical--articulo-X0300893299000135?redirect=true
Peña M, Palomino J, Ochoa J, Barriales R. Diagnóstico y tratamiento de la miocardiopatía hipertrófica: comparación de las guías europeas y americanas. Cardiocore. 2015 [acceso 02/03/2022];50(2):76-9. Disponible en: https://www.elsevier.es/es-revista-cardiocore-298-articulo-diagnostico-tratamiento-miocardiopatia-hipertrofica-comparacion-S1889898X14001248
Spertus JA, Fine JT, Elliott P, Ho C, Olivotto, I, Saberi S, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomized, double-blind, placebo-controlled, phase 3 trial. Lancet. 2021;397(10293):2467-75. DOI: https://doi.org/10.1016/S0140-6736(21)00763-7